

ASX RELEASE | OSTEOPORE LIMITED

Change of Directors' Interest Notice

25 February 2022: Osteopore Limited (ASX: OSX) ("Osteopore" or the "Company"), advises that the attached Appendix 3Y Change of Directors' Interest Notice for Company Director Professor Teoh Swee Hin, relates only to a transfer of his existing fully paid ordinary shares to Citicorp Nominees as his custodian.

There are no other changes to Professor Teoh's holdings.

This announcement has been approved for release by the Chairman of Osteopore.

For more information, please contact:

Mark Leong

Executive Chairman

Osteopore Limited

+65 9011 7009

Mark Leong@osteopore.com

About Osteopore Limited

Osteopore Ltd is an Australian and Singapore based medical technology company commercialising a range of bespoke products specifically engineered to facilitate bone healing across multiple therapeutic areas. Osteopore's patented technology fabricates specific micro-structured scaffolds for bone regeneration through 3D printing and bioresorbable material.

Osteopore's patent-protected scaffolds are made from proprietary polymer formulations, that naturally dissolve over time to leave only natural, healthy bone tissue, significantly reducing post-surgery complications commonly associated with permanent bone implants.

Rule 3.19A.2

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Osteopore Limited
ABN	65 630 538 957

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Teoh Swee Hin
Date of last notice	27 November 2019

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Citicorp Nominees Pty Limited, as custodian for Professor Teoh Swee Hin.
Date of change	18 February 2022
No. of securities held prior to change	Teoh Swee Hin 7,030,309 fully paid ordinary shares 1,500,000 Unlisted Options exercisable at \$0.25 per option, expiring 30 June 2022.
	Citicorp Nominees Pty Limited, as custodian for Professor Teoh Swee Hin

⁺ See chapter 19 for defined terms.

Fully paid ordinary shares	
N/A	
Transfer of fully paid ordinary shares from direct holding to indirect (custodian) holding only.	
N/A	
Transfer of fully paid ordinary shares from direct holding to indirect (custodian) holding only.	
N/A	
Transfer of fully paid ordinary shares from direct holding to indirect (custodian) holding only.	
Teoh Swee Hin	
1,500,000 Unlisted Options exercisable at \$0.25 per option, expiring 30 June 2022.	
Citicorp Nominees Pty Limited, as custodian for Professor Teoh Swee Hin	
7,030,309 fully paid ordinary shares.	
Transfer of fully paid ordinary shares from direct holding to indirect (custodian) holding only.	

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A

⁺ See chapter 19 for defined terms.

Appendix 3Y Page 2 01/01/2011

No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – *Closed period

Were the interests in the securities or contracts detailed above traded during a *closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See chapter 19 for defined terms.